PILO, Maria Giulia
 Distribuzione geografica
Continente #
NA - Nord America 491
EU - Europa 210
AS - Asia 116
OC - Oceania 3
AF - Africa 2
Continente sconosciuto - Info sul continente non disponibili 2
Totale 824
Nazione #
US - Stati Uniti d'America 490
UA - Ucraina 83
CN - Cina 71
IT - Italia 56
DE - Germania 31
ID - Indonesia 16
SG - Singapore 16
FI - Finlandia 10
CZ - Repubblica Ceca 9
SE - Svezia 9
TR - Turchia 4
AU - Australia 3
FR - Francia 3
IR - Iran 3
AT - Austria 2
BE - Belgio 2
DZ - Algeria 2
KR - Corea 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CA - Canada 1
DK - Danimarca 1
EU - Europa 1
GB - Regno Unito 1
IN - India 1
IQ - Iraq 1
JP - Giappone 1
NL - Olanda 1
Totale 824
Città #
Chandler 154
Jacksonville 55
Sassari 35
Princeton 34
Nanjing 20
Ashburn 18
Mountain View 15
Wilmington 14
Woodbridge 13
Dearborn 11
Ann Arbor 10
Beijing 10
Houston 10
New York 10
Singapore 10
Brno 9
Fairfield 8
Jinan 6
Nanchang 6
Shenyang 5
Boardman 4
Cagliari 4
Izmir 4
Jiaxing 4
Monmouth Junction 4
Norwalk 4
Seattle 4
Changsha 3
Hebei 3
Helsinki 3
Ningbo 3
Algiers 2
Ardabil 2
Augusta 2
Brussels 2
Cambridge 2
Como 2
Guangzhou 2
Seoul 2
Tianjin 2
Vienna 2
Alghero 1
Andover 1
Baghdad 1
Carbonia 1
Fremont 1
Fuzhou 1
Hangzhou 1
Hefei 1
Kunming 1
Lanzhou 1
Leawood 1
Marrùbiu 1
Melbourne 1
Milan 1
Motru 1
Mumbai 1
Munich 1
Osaka 1
Ottawa 1
Redwood City 1
Rockville 1
San Mateo 1
Sydney 1
Taizhou 1
Tappahannock 1
Utrecht 1
Washington 1
Zhengzhou 1
Totale 541
Nome #
Pathogenetic, Prognostic, and Therapeutic Role of Fatty Acid Synthase in Human Hepatocellular Carcinoma 89
Jagged 1 is a major Notch ligand along cholangiocarcinoma development in mice and humans 69
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis 65
Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans 63
A functional mammalian target of rapamycin complex 1 signaling is indispensable for c-Myc-driven hepatocarcinogenesis 60
Both de novo synthetized and exogenous fatty acids support the growth of hepatocellular carcinoma cells 55
Co-activation of AKT and c-Met triggers rapid hepatocellular carcinoma development via the mTORC1/FASN pathway in mice 52
Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma 52
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models 47
Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice 45
Activated mutant forms of PIK3CA cooperate with RasV12 or c-Met to induce liver tumour formation in mice via AKT2/mTORC1 cascade 44
Differential requirement for de novo lipogenesis in cholangiocarcinoma and hepatocellular carcinoma of mice and humans 40
Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma 37
Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines in vitro and AKT-driven hepatocarcinogenesis in mice 36
Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma 33
La Completa inibizione della via di segnale mTORC1 è necessaria per la soppressione dell’epatocancerogenesi indotta dall’iperespressione dei protooncogeni AKT e N-Ras nel topo 29
The Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease 21
Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade 20
Totale 857
Categoria #
all - tutte 4.514
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.514


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020137 35 0 8 1 12 9 25 1 19 5 22 0
2020/2021175 16 0 65 1 17 2 20 0 21 17 15 1
2021/202279 3 0 0 2 0 0 2 2 6 3 23 38
2022/2023257 28 35 6 39 20 35 0 31 43 2 10 8
2023/202494 12 8 4 1 26 7 1 12 0 3 4 16
2024/20256 6 0 0 0 0 0 0 0 0 0 0 0
Totale 857